Compare $ALGS vs $QNCX | Chartloom

Compare

$ALGS vs $QNCX

Aligos Therapeutics Inc · Quince Therapeutics Inc

ALGS

Aligos Therapeutics Inc

QNCX

Quince Therapeutics Inc

Compare $ALGS vs $QNCX

Comparing Aligos Therapeutics Inc and Quince Therapeutics Inc

ALGSAligos Therapeutics Inc

QNCXQuince Therapeutics Inc

ALGSAligos Therapeutics Inc

Market cap

$33M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

4.83x

Rev growth (TTM)

893.0%

YTD performance

-41.5%

52W performance

-46.2%

FCF yield

-286.0%

QNCXQuince Therapeutics Inc

Market cap

$31M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-94.7%

52W performance

-91.7%

FCF yield

-151.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ALGS

QNCX

Detailed metrics comparison

ALGS

Aligos Therapeutics Inc

QNCX

Quince Therapeutics Inc

Market Cap

ALGS$33M

QNCX$31M

Enterprise Value

ALGS$3M

QNCX$-85M

Price

ALGS$5.34

QNCX$31.73

P/E Ratio

ALGSN/A

QNCXN/A

P/S Ratio

ALGS1.05x

QNCX0.00x

EV/Sales

ALGS0.09x

QNCX0.00x

EV/EBITDA

ALGS0.00x

QNCX0.00x

P/B Ratio

ALGS1.09x

QNCX0.27x

P/FCF Ratio

ALGSN/A

QNCXN/A

EV/FCF

ALGS-0.03x

QNCX1.81x

PEG Ratio

ALGSN/A

QNCXN/A

Forward P/E (NTM)

ALGSN/A

QNCXN/A

Forward P/S (NTM)

ALGS4.83x

QNCXN/A

Revenue (TTM)

ALGS$32M

QNCX$0

Revenue Growth (YoY)

ALGS893.0%

QNCXN/A

Forward Rev Growth

ALGS-84.9%

QNCX114.8%

Gross Margin (TTM)

ALGS0.0%

QNCX0.0%

Operating Margin (TTM)

ALGS0.0%

QNCX0.0%

EBITDA Margin (TTM)

ALGS-247.2%

QNCX0.0%

Net Margin (TTM)

ALGS-241.0%

QNCX0.0%

FCF Margin (TTM)

ALGS-299.9%

QNCXN/A

Net Income (TTM)

ALGS$-76M

QNCX$-92M

FCF (TTM)

ALGS$-95M

QNCX$-47M

EPS (TTM)

ALGS-$7.28

QNCX-$15.08

ROE (TTM)

ALGS-16072.0%

QNCX-12702.0%

ROA (TTM)

ALGS-9230.0%

QNCX-10448.0%

ROIC (TTM)

ALGS-16035.0%

QNCX-11143.0%

Cash

ALGS$30M

QNCX$116M

Debt

ALGS$64K

QNCX$0

Net Cash/Debt

ALGS$30M

QNCX$116M

Current Ratio (TTM)

ALGS2.19x

QNCX14.52x

Quick Ratio (TTM)

ALGS2.19x

QNCX14.28x

Debt/Equity (TTM)

ALGS0.00x

QNCX0.48x

Debt/Assets (TTM)

ALGS0.0%

QNCX0.0%

Interest Coverage (TTM)

ALGSN/A

QNCXN/A

Net Debt/EBITDA (TTM)

ALGS0.00x

QNCX0.00x

Beta

ALGS2.48

QNCX1.80

52W Performance

ALGS-46.2%

QNCX-91.7%

YTD Performance

ALGS-41.5%

QNCX-94.7%

% from 52W High

ALGS-61.0%

QNCX-96.5%

% from 52W Low

ALGS34.2%

QNCX110.1%

Asset Turnover (TTM)

ALGS0.38x

QNCX0.00x

FCF Yield (TTM)

ALGS-286.0%

QNCX-151.2%

Earnings Yield (TTM)

ALGS-229.8%

QNCX-297.4%

Dividend Yield (TTM)

ALGSN/A

QNCXN/A

Rule of 40

ALGS593.1

QNCX0.0

EV/GP/RG

ALGSN/A

QNCXN/A

Ticker research

View ALGS research View QNCX research

Metric	ALGS Aligos Therapeutics Inc	QNCX Quince Therapeutics Inc
Market & Valuation
Market Cap	$33M	$31M
Enterprise Value	$3M	$-85M
Price	$5.34	$31.73
P/E Ratio	N/A	N/A
P/S Ratio	1.05x	0.00x
EV/Sales	0.09x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.09x	0.27x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.03x	1.81x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	4.83x	N/A
Revenue & Growth
Revenue (TTM)	$32M	$0
Revenue Growth (YoY)	893.0%	N/A
Forward Rev Growth	-84.9%	114.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-247.2%	0.0%
Net Margin (TTM)	-241.0%	0.0%
FCF Margin (TTM)	-299.9%	N/A
Net Income (TTM)	$-76M	$-92M
FCF (TTM)	$-95M	$-47M
EPS (TTM)	-$7.28	-$15.08
ROE (TTM)	-16072.0%	-12702.0%
ROA (TTM)	-9230.0%	-10448.0%
ROIC (TTM)	-16035.0%	-11143.0%
Financial Health
Cash	$30M	$116M
Debt	$64K	$0
Net Cash/Debt	$30M	$116M
Current Ratio (TTM)	2.19x	14.52x
Quick Ratio (TTM)	2.19x	14.28x
Debt/Equity (TTM)	0.00x	0.48x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.48	1.80
52W Performance	-46.2%	-91.7%
YTD Performance	-41.5%	-94.7%
% from 52W High	-61.0%	-96.5%
% from 52W Low	34.2%	110.1%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.00x
FCF Yield (TTM)	-286.0%	-151.2%
Earnings Yield (TTM)	-229.8%	-297.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	593.1	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ALGS research	View QNCX research

Valuation

P/S Ratio

QNCX

0.00x

ALGS

1.05x

EV/FCF

ALGS

-0.03x

QNCX

1.81x

Growth & revenue

Revenue Growth TTM

ALGS

893.0%

Forward Revenue Growth

QNCX

114.8%

ALGS

-84.9%

Profitability & performance

Gross Margin

ALGS

0.0%

QNCX

0.0%

ROE

QNCX

-12702.0%

ALGS

-16072.0%

FCF Yield %

QNCX

-151.2%

ALGS

-286.0%

52-Week Performance

ALGS

-46.2%

QNCX

-91.7%

Detailed metrics comparison

ALGS

Aligos Therapeutics Inc

QNCX

Quince Therapeutics Inc

Market Cap

ALGS$33M

QNCX$31M

Enterprise Value

ALGS$3M

QNCX$-85M

Price

ALGS$5.34

QNCX$31.73

P/E Ratio

ALGSN/A

QNCXN/A

P/S Ratio

ALGS1.05x

QNCX0.00x

EV/Sales

ALGS0.09x

QNCX0.00x

EV/EBITDA

ALGS0.00x

QNCX0.00x

P/B Ratio

ALGS1.09x

QNCX0.27x

P/FCF Ratio

ALGSN/A

QNCXN/A

EV/FCF

ALGS-0.03x

QNCX1.81x

PEG Ratio

ALGSN/A

QNCXN/A

Forward P/E (NTM)

ALGSN/A

QNCXN/A

Forward P/S (NTM)

ALGS4.83x

QNCXN/A

Revenue (TTM)

ALGS$32M

QNCX$0

Revenue Growth (YoY)

ALGS893.0%

QNCXN/A

Forward Rev Growth

ALGS-84.9%

QNCX114.8%

Gross Margin (TTM)

ALGS0.0%

QNCX0.0%

Operating Margin (TTM)

ALGS0.0%

QNCX0.0%

EBITDA Margin (TTM)

ALGS-247.2%

QNCX0.0%

Net Margin (TTM)

ALGS-241.0%

QNCX0.0%

FCF Margin (TTM)

ALGS-299.9%

QNCXN/A

Net Income (TTM)

ALGS$-76M

QNCX$-92M

FCF (TTM)

ALGS$-95M

QNCX$-47M

EPS (TTM)

ALGS-$7.28

QNCX-$15.08

ROE (TTM)

ALGS-16072.0%

QNCX-12702.0%

ROA (TTM)

ALGS-9230.0%

QNCX-10448.0%

ROIC (TTM)

ALGS-16035.0%

QNCX-11143.0%

Cash

ALGS$30M

QNCX$116M

Debt

ALGS$64K

QNCX$0

Net Cash/Debt

ALGS$30M

QNCX$116M

Current Ratio (TTM)

ALGS2.19x

QNCX14.52x

Quick Ratio (TTM)

ALGS2.19x

QNCX14.28x

Debt/Equity (TTM)

ALGS0.00x

QNCX0.48x

Debt/Assets (TTM)

ALGS0.0%

QNCX0.0%

Interest Coverage (TTM)

ALGSN/A

QNCXN/A

Net Debt/EBITDA (TTM)

ALGS0.00x

QNCX0.00x

Beta

ALGS2.48

QNCX1.80

52W Performance

ALGS-46.2%

QNCX-91.7%

YTD Performance

ALGS-41.5%

QNCX-94.7%

% from 52W High

ALGS-61.0%

QNCX-96.5%

% from 52W Low

ALGS34.2%

QNCX110.1%

Asset Turnover (TTM)

ALGS0.38x

QNCX0.00x

FCF Yield (TTM)

ALGS-286.0%

QNCX-151.2%

Earnings Yield (TTM)

ALGS-229.8%

QNCX-297.4%

Dividend Yield (TTM)

ALGSN/A

QNCXN/A

Rule of 40

ALGS593.1

QNCX0.0

EV/GP/RG

ALGSN/A

QNCXN/A

Ticker research

View ALGS research View QNCX research

Metric	ALGS Aligos Therapeutics Inc	QNCX Quince Therapeutics Inc
Market & Valuation
Market Cap	$33M	$31M
Enterprise Value	$3M	$-85M
Price	$5.34	$31.73
P/E Ratio	N/A	N/A
P/S Ratio	1.05x	0.00x
EV/Sales	0.09x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.09x	0.27x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.03x	1.81x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	4.83x	N/A
Revenue & Growth
Revenue (TTM)	$32M	$0
Revenue Growth (YoY)	893.0%	N/A
Forward Rev Growth	-84.9%	114.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-247.2%	0.0%
Net Margin (TTM)	-241.0%	0.0%
FCF Margin (TTM)	-299.9%	N/A
Net Income (TTM)	$-76M	$-92M
FCF (TTM)	$-95M	$-47M
EPS (TTM)	-$7.28	-$15.08
ROE (TTM)	-16072.0%	-12702.0%
ROA (TTM)	-9230.0%	-10448.0%
ROIC (TTM)	-16035.0%	-11143.0%
Financial Health
Cash	$30M	$116M
Debt	$64K	$0
Net Cash/Debt	$30M	$116M
Current Ratio (TTM)	2.19x	14.52x
Quick Ratio (TTM)	2.19x	14.28x
Debt/Equity (TTM)	0.00x	0.48x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.48	1.80
52W Performance	-46.2%	-91.7%
YTD Performance	-41.5%	-94.7%
% from 52W High	-61.0%	-96.5%
% from 52W Low	34.2%	110.1%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.00x
FCF Yield (TTM)	-286.0%	-151.2%
Earnings Yield (TTM)	-229.8%	-297.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	593.1	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ALGS research	View QNCX research